NYSEAMERICAN:APHBAmpliphi Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ampliphi Biosciences Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.95 +0.23 (+6.18 %) (As of 07/14/2020) Add Compare Share Today's Range$3.76Now: $3.95▼$3.9950-Day Range N/A52-Week Range$0.15Now: $3.95▼$1.37Volume36,257 shsAverage Volume841,593 shsMarket Capitalization$132.20 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections. It holds collaborative research and development agreements with the United States Army Medical Research and Materiel Command for the development of bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and Walter Reed Army Institute of Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Ampliphi Biosciences. Previous Next 2.8 Community Rank Outperform VotesAmpliphi Biosciences has received 205 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAmpliphi Biosciences has received 165 “underperform” votes. (Add your “underperform” vote.)Community SentimentAmpliphi Biosciences has received 55.41% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Ampliphi Biosciences and other stocks. Vote “Outperform” if you believe APHB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe APHB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAmpliphi Biosciences does not currently pay a dividend.Dividend GrowthAmpliphi Biosciences does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ampliphi Biosciences insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.56 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:APHB Previous SymbolAMEX:APHB CUSIPN/A CIK921114 Webwww.ampliphibio.com Phone+1-804-8272524Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees30 Outstanding Shares33,469,000Market Cap$132.20 million Next Earnings DateN/A OptionableNot Optionable $3.95 +0.23 (+6.18 %) (As of 07/14/2020) 30 days | 90 days | 365 days | Advanced Chart Receive APHB News and Ratings via Email Sign-up to receive the latest news and ratings for APHB and its competitors with MarketBeat's FREE daily newsletter. Ampliphi Biosciences (NYSEAMERICAN:APHB) Frequently Asked Questions How were Ampliphi Biosciences' earnings last quarter? Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) posted its quarterly earnings data on Monday, March, 25th. The biotechnology company reported ($0.15) EPS for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.07. View Ampliphi Biosciences' earnings history. Has Ampliphi Biosciences been receiving favorable news coverage? Press coverage about APHB stock has trended somewhat negative recently, according to InfoTrie. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ampliphi Biosciences earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the near term. View the latest news about Ampliphi Biosciences. Who are some of Ampliphi Biosciences' key competitors? Some companies that are related to Ampliphi Biosciences include Ibio (IBIO), CEL-SCI (CVM), Paradigm Biopharmaceuticals (PAR), Biotest (BIO), IMV (IMV), Neptune Wellness Solutions (NEPT), Inventiva (IVA), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX), Starpharma (SPL), Tiziana Life Sciences (TILS), IMV (IMV), ProMetic Life Sciences (PLI), Synairgen (SNG) and Fennec Pharmaceuticals (FRX). View all competitors. What other stocks do shareholders of Ampliphi Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ampliphi Biosciences investors own include Navios Maritime Partners (NMM), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Protalix Biotherapeutics (PLX), Eyepoint Pharmaceuticals (EYPT), Verastem (VSTM), AcelRx Pharmaceuticals (ACRX), Athersys (ATHX) and Actinium Pharmaceuticals (ATNM). Who are Ampliphi Biosciences' key executives? Ampliphi Biosciences' management team includes the following people: Dr. Paul C. Grint, CEO & Director (Age 61)Mr. Steven R. Martin, Sr. VP & CFO (Age 58)Mr. Michael Scott Salka, Consultant (Age 57) What is Ampliphi Biosciences' stock symbol? Ampliphi Biosciences trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "APHB." How do I buy shares of Ampliphi Biosciences? Shares of APHB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Ampliphi Biosciences' stock price today? One share of APHB stock can currently be purchased for approximately $3.95. How big of a company is Ampliphi Biosciences? Ampliphi Biosciences has a market capitalization of $132.20 million. Ampliphi Biosciences employs 30 workers across the globe. What is Ampliphi Biosciences' official website? The official website for Ampliphi Biosciences is www.ampliphibio.com. How can I contact Ampliphi Biosciences? Ampliphi Biosciences' mailing address is 3579 Valley Centre Drive, SAN DIEGO, CA 92130, United States. The biotechnology company can be reached via phone at +1-804-8272524. This page was last updated on 8/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
